BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms associated with long COVID.

BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston from April 23 to 25. Additionally, the company said that bezisterim has been approved as the generic name for NE3107 by the United States Adopted Names Council and World Health Organization International Nonproprietary Names expert committee.

BioVie presents new data showing lead drug asset may promote healthier aging

CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Genetic Technologies

ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET).

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SAN DIEGO , March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in BioVie Inc. (NASDAQ: BIVI) shares. Investors, who purchased shares of BioVie Inc. (NASDAQ: BIVI) prior to August 2021 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71801&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 – BIVI

NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) and certain officers. The class action, filed in the United States ("U.S.") District Court for the District of Nevada, and docketed under 24-cv-00361, is on behalf of persons or entities who purchased or otherwise acquired publicly traded BioVie securities from August 5, 2021 through November 29, 2023, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71772&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioVie Inc.(BIVI) Shareholders

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71683&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against BioVie Inc. (BIVI) Seeking Recovery for Investors - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71624&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71647&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71561&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71532&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 19, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) securities between August 5, 2021 through November 29, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 8, 2023, BioVie disclosed that, for the Phase 3 cli.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71521&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Class Action: Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71467&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / March 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71400&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71374&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)

NEW YORK, NY / ACCESSWIRE / March 16, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71353&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in BioVie Lawsuit - BIVI

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71296&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in BioVie Inc. Lawsuit - BIVI

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71280&wire=1 or contact Joseph E. Levi, Esq.

News for BioVie Inc Stock (BIVI)